Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds
Adlyxin (lixisenatide) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.
Soliqua is the first insulin/GLP-1 agonist combo to hit the market. It contains Lantus (insulin glargine U-100) plus Adlyxin.